Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 7;8:21. doi: 10.1038/s41536-023-00293-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a, b Immunostaining showing that Mef2C⁺ and PCNA⁺ proliferating cardiomyocytes of control (a) and endothelial NICD-overexpressing heart sections (b) at 7 dpa after 4-HT induction. c Statistics of panels (a) and (b) (data are the mean fold change ± s.e.m.; **p < 0.01, unpaired t-test). d–i Representative images of immunostaining showing that, compared with control siRNA treatment (d), PCNA⁺/Mef2C⁺ proliferating cardiomyocytes decreased at 7 dpa in DN-xBrg1 hearts (DN) treated with control siRNA (e), which were partially rescued by either notch1a (f), notch1b (g), notch2 (h), or notch3 (i) siRNA treatment in the presence of 4-HT. Scale bar, 100 μm. j Statistics of panels (d–i) (data are the mean ± s.e.m.; *p < 0.05; **p < 0.01; ***p < 0.005; one-way analysis of variance [F = 32.5] followed by Dunnett’s multiple comparison test). k–n Representative images of immunostaining at 7 dpa showing that, compared with DMSO treatment (k), PCNA⁺/Mef2C⁺ proliferating cardiomyocytes in DN mutant hearts decreased (l), which were partially rescued by either DAPT (m) or MK-0752 treatment (n) in the presence of 4-HT. Scale bar, 100 μm. o Statistics of panels (k–n) (data were the mean ± s.e.m.; ***p < 0.005; one-way analysis of variance [F = 22.4] followed by Dunnett’s multiple comparison test). n number shown here (c, j, o) indicated biological replicates.